References
- Craig FE, Gulley ML, Banks PM. Post-transplantation lymphoproliferative disorders. Am J Clin Pathol 1993; 99: 265–76
- Khanna R, Bell S, Sherritt M, et al. Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in a solid organ transplant patient with post transplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999; 96: 10391–16
- Sherritt MA, Bharadwaj M., Burrows JM, et al. Reconstitution of the latent T lymphocyte response to Epstein–Barr virus is coincident with long-term recovery from post transplant lymphoma following adoptive immunotherapy. Transplantation 2003; 15;75: 1556–60
- Gandhi MK, Wilkie GM, Dua U , et al. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for post-transplant lymphoproliferative disorders. Am J Transplant in press.
- Hill GR, Morris ES, Fuery M, et al. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated-G-CSF. Biol Blood Marrow Transplant 2006; 12: 603–7
- Morris ES, Macdonald KP, Hill GR. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?. Blood 2006; 107: 3430–5
- Morris ES, MacDonald KP, Rowe R, et al. NKT cell-dependent leukaemia eradication following stem cell mobilization with potent G-CSF analogues. J Clin Invest 2005; 115: 3093–103
- Westwood JA, Smyth MJ, Teng MW, et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA 2005; 102: 19051–6
- Duraiswamy J, Bharadwaj M, Tellam J, et al. Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Res 2004; 64: 1483–9
- Foster AE, Bradstock KF, Sili U, et al. A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2-donors. Biol Blood Marrow Transplant 2004; 10: 761–71
- Mattarollo SR, Kenna A, Nieda M, Nicol AJ. Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity. Cancer Immunol Immunother 2007, Jan 31; Epub ahead of print.